---
title: "Y-Mabs Therapeutics | 8-K: FY2025 Q2 Revenue Beats Estimate at USD 19.53 M"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/252216770.md"
published_at: "2025-08-08T11:19:32.000Z"
---

# Y-Mabs Therapeutics | 8-K: FY2025 Q2 Revenue Beats Estimate at USD 19.53 M

Revenue: As of FY2025 Q2, the actual value is USD 19.53 M, beating the estimate of USD 18.4 M.

EPS: As of FY2025 Q2, the actual value is USD -0.07, beating the estimate of USD -0.2625.

EBIT: As of FY2025 Q2, the actual value is USD -5.604 M.

### Segment Revenue

-   Total revenues for the quarter ended June 30, 2025, were $19.5 million, a 14% decrease from $22.8 million in the same period in 2024. This decrease was driven by a $2.9 million decrease in Ex-U.S. DANYELZA net product revenues and a $0.9 million decrease in U.S. DANYELZA net product revenues, partially offset by a $0.5 million increase in license revenue.

### Operational Metrics

-   Gross profit for the quarter ended June 30, 2025, was $16.8 million, compared to $19.8 million for the same period in 2024, with gross margins of 86% and 87%, respectively.
-   Research and development expenses decreased to $11.1 million from $12.3 million for the quarter ended June 30, 2024.
-   Selling, general, and administrative expenses were $11.3 million, down from $17.2 million in the same period in 2024.
-   Net loss for the quarter ended June 30, 2025, was $3.2 million, compared to a net loss of $9.2 million for the same period in 2024.

### Cash Flow

-   As of June 30, 2025, cash and cash equivalents were $62.3 million.
-   Net cash used in operating activities for the six months ended June 30, 2025, was $5.3 million, compared to $3.2 million for the same period in 2024.

### Unique Metrics

-   The company recognized $0.5 million in license revenue during the three months ended June 30, 2025, related to sales-based milestone achievements by a partner in Israel.

### Outlook / Guidance

-   Y-mAbs announced a definitive agreement for acquisition by SERB Pharmaceuticals valued at $412.0 million, expected to close by the fourth quarter of 2025, subject to customary conditions.

### Related Stocks

- [YMAB.US - Y-Mabs Therapeutics](https://longbridge.com/en/quote/YMAB.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Y-mAbs Therapeutics, Inc. $YMAB Stake Lifted by Acorn Capital Advisors LLC | Acorn Capital Advisors LLC increased its stake in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) by 13.1% in Q1, now holding 3, | [Link](https://longbridge.com/en/news/255463534.md) |
| Y-mAbs Therapeutics Inc. Completes Merger with Perseus BidCo US, Inc., Becoming Wholly Owned Subsidiary | Y-mAbs Therapeutics, Inc. has successfully merged with Yosemite Merger Sub, Inc., a subsidiary of Perseus BidCo US, Inc. | [Link](https://longbridge.com/en/news/257560458.md) |
| Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2026 \| APLIF Stock News | Appili Therapeutics Inc. reported its financial and operational results for Q3 FY 2026, highlighting US$82 million in pe | [Link](https://longbridge.com/en/news/275821612.md) |
| 08:00 ETSmith Brands Opens Wholesale Orders for WET FARTS® | Smith Brands has announced that its viral prank product, WET FARTS®, is now available for wholesale orders to retail par | [Link](https://longbridge.com/en/news/275980092.md) |
| 13:25 ETSEO for Lawyers, LLC Secures Federal Trademark Registration for LAWSEO® | SEO for Lawyers, LLC has secured federal trademark registration for LAWSEO®, confirming its exclusive ownership and mark | [Link](https://longbridge.com/en/news/275794622.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.